These are the stocks posting the largest moves before the bell.Market Insiderread more
Allergan shareholders will receive 0.8660 AbbVie shares and $120.30 in cash for each share held, for a total value of $188.24 per Allergan share.Biotech and Pharmaceuticalsread more
Amazon announces that Amazon Prime Day will last for two days, starting July 15.Technologyread more
Home prices in April were 3.5% higher than a year earlier, according to the S&P CoreLogic Case-Shiller U.S. National Home Price Index.Real Estateread more
Joe Biden could face some uncomfortable questions about his record on women this week at the first Democratic presidential debates in Miami.2020 Electionsread more
"What else do you have to do that will actually have to affect the Iranians' calculus?" said Amos Hochstein, who served as U.S. special envoy for international energy affairs...World Politicsread more
FedEx heads into Tuesday afternoon's earnings deep in a bear market. A failure to deliver could mark a massive buying opportunity.Trading Nationread more
Investors are piling into gold, sending the precious metal to a six-year high on Monday, and analysts think the commodity has established a base to go even higher.Marketsread more
Here are the biggest calls on Wall Street on TuesdayInvestingread more
Gold prices hit their highest level in six years on Tuesday as investors plowed into the precious metal amid the prospects of lower interest rates and tensions between Iran...Marketsread more
In a new interview with CBS's Gayle King, Adam Mosseri addressed a common suspicion about how Instagram targets ads.Technologyread more
Alphabet's Calico and AbbVie first partnered in 2014 to combat age-related diseases, including cancers and neurodegenerative diseases. The additional contributions bring Calico's total funding to $2.5 billion.
Aging is an attractive area in the biotechnology space as companies look for ways to ease the challenges that come with growing old. The Food and Drug Administration does not consider aging a disease, so some companies are tackling diseases associated with it rather than aging itself.
Together, AbbVie and Calico have produced more than two dozen early-stage programs focused on diseases in oncology and neurosciences.
Under the agreement, Calico is responsible for research and early development until 2022 and will be responsible for Phase 2a trials through 2027. After that, AbbVie will have the option to manage late-stage development. AbbVie will help lead commercialization efforts.